Predialysis calcitriol administration: effects on pre- and post-transplant renal osteodystrophy

Twins with parallel loss of kidney function and moderate hyperparathyroid bone disease were participants in a double-blind study where twin A was given placebo and twin B calcitriol. After 8 months. A's bone disease had not improved, while B's bone had normalized. Thereafter, both received...

Full description

Saved in:
Bibliographic Details
Published inJournal of internal medicine Vol. 239; no. 6; p. 537
Main Authors Dahl, E, Nordal, K P, Halse, J
Format Journal Article
LanguageEnglish
Published England 01.06.1996
Subjects
Calcitriol - administration & dosage
Child
Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy
Diseases in Twins
Double-Blind Method
Drug Administration Schedule
Humans
Male
Randomized Controlled Trials as Topic
Renal Dialysis
Time Factors
Online AccessGet more information

Cover

More Information
Summary:Twins with parallel loss of kidney function and moderate hyperparathyroid bone disease were participants in a double-blind study where twin A was given placebo and twin B calcitriol. After 8 months. A's bone disease had not improved, while B's bone had normalized. Thereafter, both received calcitriol until kidney transplantation 11 months later, when both had normal bone structure. Two years after transplantation, both twins had hyperparathyroid bone disease, but A had more pronounced changes. This report illustrates our findings in larger series: When started early in the course of renal failure, calcitriol can reverse pre-transplant hyperparathyroid bone disease and also influence post-transplant bone disease.
ISSN:0954-6820
DOI:10.1046/j.1365-2796.1996.428780000.x